Follow up analysis of phase III study of gefitinib versus erlotinib in patients with advanced lung adenocarcinoma.
Not Applicable
- Conditions
- Previously treated advanced lung adenocarcinoma
- Registration Number
- JPRN-UMIN000030082
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 561
Inclusion Criteria
Not provided
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival of patients with activating mutation according to treatment arm
- Secondary Outcome Measures
Name Time Method Efficacy of brain metastasis in patients with brain metastasis according to treatment arm